For patients with HER2-positive early BC and invasive residual disease after neoadjuvant therapy, an ongoing, prospective, phase III trial (CompassHER2 RD [NCT04457596]) will evaluate the addition of tucatinib to T-DM1 in preventing relapse in this high-risk population. Here, ERBB2 is linked to breast cancer.